OP Asset Management Ltd Takes Position in Xencor, Inc. $XNCR

OP Asset Management Ltd purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 55,082 shares of the biopharmaceutical company’s stock, valued at approximately $664,000. OP Asset Management Ltd owned about 0.08% of Xencor as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. boosted its holdings in shares of Xencor by 620.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after acquiring an additional 620,440 shares in the last quarter. Baker BROS. Advisors LP grew its position in Xencor by 64.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock worth $12,928,000 after acquiring an additional 431,675 shares during the last quarter. Vanguard Group Inc. increased its holdings in Xencor by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after purchasing an additional 61,692 shares in the last quarter. Erste Asset Management GmbH increased its holdings in Xencor by 26.3% during the 4th quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock valued at $7,347,000 after purchasing an additional 100,000 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Xencor by 21.7% during the third quarter. JPMorgan Chase & Co. now owns 401,501 shares of the biopharmaceutical company’s stock worth $4,710,000 after purchasing an additional 71,494 shares during the last quarter.

Xencor Trading Up 3.2%

Shares of NASDAQ XNCR opened at $16.10 on Wednesday. The firm has a market capitalization of $1.19 billion, a PE ratio of -7.03 and a beta of 0.92. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The firm’s 50-day moving average is $12.45 and its 200-day moving average is $12.81.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million for the quarter, compared to the consensus estimate of $27.86 million. During the same period last year, the firm earned ($0.66) earnings per share. The company’s quarterly revenue was down 86.2% on a year-over-year basis. As a group, equities research analysts anticipate that Xencor, Inc. will post -3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Zacks Research downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Hold” and a consensus target price of $24.50.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.